Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence.  

Pesquisa com 2.950 mulheres mostrou que 43% tinham idade inferior a 50 anos no momento do diagnóstico do tumor, ou seja, antes da idade inicial de recomendação do exame pelo Ministério da Saúde.  

Only one in five low- and middle-income countries has the data necessary to drive cancer policy. The Latin American Cooperative Oncology Group strives to change that, applying SAS® Analytics to data from thousands of the region’s cancer patients to improve care and inform better health policy that saves lives